
Marc C Chamberlain

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3167840/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group. Journal of Clinical Oncology, 2010, 28, 1963-1972.	0.8	3,222
2	Phase III Study of Enzastaurin Compared With Lomustine in the Treatment of Recurrent Intracranial Glioblastoma. Journal of Clinical Oncology, 2010, 28, 1168-1174.	0.8	450
3	Randomized Trial of a Slow-Release Versus a Standard Formulation of Cytarabine for the Intrathecal Treatment of Lymphomatous Meningitis. Journal of Clinical Oncology, 1999, 17, 3110-3116.	0.8	393
4	Leptomeningeal metastasis. Neurology, 1990, 40, 435-435.	1.5	244
5	Adult Primary Intradural Spinal Cord Tumors: A Review. Current Neurology and Neuroscience Reports, 2011, 11, 320-328.	2.0	240
6	Historical benchmarks for medical therapy trials in surgery- and radiation-refractory meningioma: a RANO review. Neuro-Oncology, 2014, 16, 829-840.	0.6	198
7	Diagnostic Tools for Neoplastic Meningitis: Detecting Disease, Identifying Patient Risk, and Determining Benefit of Treatment. Seminars in Oncology, 2009, 36, S35-S45.	0.8	189
8	Radiographic patterns of relapse in glioblastoma. Journal of Neuro-Oncology, 2011, 101, 319-323.	1.4	183
9	Systemic therapy of brain metastases: non–small cell lung cancer, breast cancer, and melanoma. Neuro-Oncology, 2017, 19, i1-i24.	0.6	171
10	Temozolomide for treatment-resistant recurrent meningioma. Neurology, 2004, 62, 1210-1212.	1.5	167
11	Neoplastic Meningitis. Oncologist, 2008, 13, 967-977.	1.9	167
12	Leptomeningeal metastasis. Current Opinion in Oncology, 2010, 22, 627-635.	1.1	159
13	Leptomeningeal metastases: a RANO proposal for response criteria. Neuro-Oncology, 2017, 19, now183.	0.6	157
14	Temozolomide: therapeutic limitations in the treatment of adult high-grade gliomas. Expert Review of Neurotherapeutics, 2010, 10, 1537-1544.	1.4	155
15	Prognostic significance of sup 111 Indium-DTPA CSF flow studies in leptomeningeal metastases. Neurology, 1996, 46, 1674-1677.	1.5	151
16	Complications associated with intraventricular chemotherapy in patients with leptomeningeal metastases. Journal of Neurosurgery, 1997, 87, 694-699.	0.9	148
17	Leptomeningeal metastasis: a Response Assessment in Neuro-Oncology critical review of endpoints and response criteria of published randomized clinical trials. Neuro-Oncology, 2014, 16, 1176-1185.	0.6	141
18	PET imaging in patients with brain metastasis—report of the RANO/PET group. Neuro-Oncology, 2019, 21, 585-595.	0.6	139

#	Article	IF	CITATIONS
19	The Neurologic Assessment in Neuro-Oncology (NANO) scale: a tool to assess neurologic function for integration into the Response Assessment in Neuro-Oncology (RANO) criteria. Neuro-Oncology, 2017, 19, 625-635.	0.6	137
20	Carcinoma Meningitis Secondary to Non–Small Cell Lung Cancer. Archives of Neurology, 1998, 55, 506.	4.9	130
21	Salvage therapy with BRAF inhibitors for recurrent pleomorphic xanthoastrocytoma: a retrospective case series. Journal of Neuro-Oncology, 2013, 114, 237-240.	1.4	124
22	Radioisotope CSF flow studies in leptomeningeal metastases. , 1998, 38, 135-140.		117
23	Salvage therapy with single agent bevacizumab for recurrent glioblastoma. Journal of Neuro-Oncology, 2010, 96, 259-269.	1.4	117
24	Leptomeningeal metastases: a review of evaluation and treatment. , 1998, 37, 271-284.		113
25	Bevacizumab for the Treatment of Recurrent Glioblastoma. Clinical Medicine Insights: Oncology, 2011, 5, CMO.S7232.	0.6	113
26	A multicenter phase II trial of intrathecal topotecan in patients with meningeal malignancies. Neuro-Oncology, 2008, 10, 208-215.	0.6	109
27	Comparative spine imaging in leptomeningeal metastases. Journal of Neuro-Oncology, 1995, 23, 233-238.	1.4	108
28	Interferonâ€Î± for recurrent World Health Organization grade 1 intracranial meningiomas. Cancer, 2008, 113, 2146-2151.	2.0	104
29	Route of intracerebrospinal fluid chemotherapy administration and efficacy of therapy in neoplastic meningitis. Cancer, 2010, 116, 1947-1952.	2.0	99
30	Salvage chemotherapy With CPT-11 for recurrent meningioma. Journal of Neuro-Oncology, 2006, 78, 271-276.	1.4	97
31	Carcinomatous meningitis secondary to breast cancer: predictors of response to combined modality therapy. , 1997, 35, 55-64.		95
32	Seizure control as a new metric in assessing efficacy of tumor treatment in low-grade glioma trials. Neuro-Oncology, 2017, 19, 12-21.	0.6	94
33	A Phase II trial of intra-cerebrospinal fluid alpha interferon in the treatment of neoplastic meningitis. Cancer, 2002, 94, 2675-2680.	2.0	91
34	Central Nervous System Cancers, Version 1.2015. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 1191-1202.	2.3	89
35	Leukemic and lymphomatous meningitis: incidence, prognosis and treatment. Journal of Neuro-Oncology, 2005, 75, 71-83.	1.4	83
36	High-dose methotrexate and rituximab with deferred radiotherapy for newly diagnosed primary B-cell CNS lymphoma. Neuro-Oncology, 2010, 12, 736-744.	0.6	83

#	Article	IF	CITATIONS
37	Salvage chemotherapy for recurrent spinal cord ependymona. Cancer, 2002, 95, 997-1002.	2.0	82
38	Hydroxyurea for recurrent surgery and radiation refractory high-grade meningioma. Journal of Neuro-Oncology, 2012, 107, 315-321.	1.4	81
39	Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients naive to antiangiogenic therapy. Neuro-Oncology, 2018, 20, 249-258.	0.6	78
40	Chemotherapy-Related Neurotoxicity. Current Neurology and Neuroscience Reports, 2016, 16, 81.	2.0	77
41	Phase II trial of intracerebrospinal fluid etoposide in the treatment of neoplastic meningitis. Cancer, 2006, 106, 2021-2027.	2.0	74
42	Response assessment in medulloblastoma and leptomeningeal seeding tumors: recommendations from the Response Assessment in Pediatric Neuro-Oncology committee. Neuro-Oncology, 2018, 20, 13-23.	0.6	74
43	Salvage chemotherapy with CPT-11 for recurrent glioblastoma multiforme. Journal of Neuro-Oncology, 2002, 56, 183-188.	1.4	73
44	Neurotoxicity of intra-CSF liposomal cytarabine (DepoCyt) administered for the treatment of leptomeningeal metastases: a retrospective case series. Journal of Neuro-Oncology, 2012, 109, 143-148.	1.4	73
45	Quality-of-life-adjusted survival comparison of sustained-release cytosine arabinoside versus intrathecal methotrexate for treatment of solid tumor neoplastic meningitis. Cancer, 2003, 97, 3053-3060.	2.0	70
46	Bevacizumab for recurrent alkylatorâ€refractory anaplastic oligodendroglioma. Cancer, 2009, 115, 1734-1743.	2.0	70
47	A comparison between ventricular and lumbar cerebrospinal `uid cytology in adult patients with leptomeningeal metastases. Neuro-Oncology, 2001, 3, 42-45.	0.6	69
48	Central Nervous System Cancers, Version 2.2014. Journal of the National Comprehensive Cancer Network: JNCCN, 2014, 12, 1517-1523.	2.3	69
49	SEQUENTIAL SALVAGE CHEMOTHERAPY FOR RECURRENT INTRACRANIAL HEMANGIOPERICYTOMA. Neurosurgery, 2008, 63, 720-727.	0.6	66
50	Hydroxyurea for recurrent surgery and radiation refractory meningioma: a retrospective case series. Journal of Neuro-Oncology, 2011, 104, 765-771.	1.4	66
51	Central Nervous System Cancers Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2005, 3, 644.	2.3	66
52	Cerebrospinal fluid-disseminated meningioma. Cancer, 2005, 103, 1427-1430.	2.0	62
53	Temozolomide for recurrent lowâ€grade spinal cord gliomas in adults. Cancer, 2008, 113, 1019-1024.	2.0	62
54	Emerging clinical principles on the use of bevacizumab for the treatment of malignant gliomas. Cancer, 2010, 116, 3988-3999.	2.0	62

#	Article	IF	CITATIONS
55	Combined-modality Treatment of Leptomeningeal Gliomatosis. Neurosurgery, 2003, 52, 324-330.	0.6	61
56	Intracranial meningiomas: diagnosis and treatment. Expert Review of Neurotherapeutics, 2004, 4, 641-648.	1.4	59
57	Salvage chemotherapy with bevacizumab for recurrent alkylator-refractory anaplastic astrocytoma. Journal of Neuro-Oncology, 2009, 91, 359-367.	1.4	59
58	Targeted Therapy for Brain Metastases in EGFR-Mutated and ALK-Rearranged Non-Small-Cell Lung Cancer. Journal of Thoracic Oncology, 2015, 10, 1268-1278.	0.5	58
59	Neuraxis imaging in leptomeningeal metastasis: A retrospective case series Journal of Clinical Oncology, 2012, 30, 2046-2046.	0.8	58
60	Recurrent intracranial ependymoma in children: salvage therapy with oral etoposide. Pediatric Neurology, 2001, 24, 117-121.	1.0	57
61	Salvage chemotherapy with cyclophosphamide for recurrent, temozolomide-refractory glioblastoma multiforme. Cancer, 2004, 100, 1213-1220.	2.0	56
62	Leptomeningeal metastasis. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2018, 149, 169-204.	1.0	55
63	Chronic oral VP-16 for recurrent medulloblastoma. Pediatric Neurology, 1997, 17, 230-234.	1.0	54
64	Neoplastic Meningitis–Related Prognostic Significance of the Karnofsky Performance Status. Archives of Neurology, 2009, 66, 74-8.	4.9	53
65	Anaplastic astrocytoma. CNS Oncology, 2016, 5, 145-157.	1.2	51
66	Treatment of intracranial metastatic esthesioneuroblastoma. Cancer, 2002, 95, 243-248.	2.0	47
67	Leptomeningeal metastasis. Current Opinion in Neurology, 2009, 22, 665-674.	1.8	47
68	A phase 2 trial of verubulin for recurrent glioblastoma: a prospective study by the brain tumor investigational consortium (BTIC). Journal of Neuro-Oncology, 2014, 118, 335-343.	1.4	46
69	Nivolumab for patients with recurrent glioblastoma progressing on bevacizumab: a retrospective case series. Journal of Neuro-Oncology, 2017, 133, 561-569.	1.4	43
70	Temozolomide for recurrent intracranial supratentorial platinumâ€refractory ependymoma. Cancer, 2009, 115, 4775-4782.	2.0	42
71	Medical treatment of recurrent meningiomas. Expert Review of Neurotherapeutics, 2011, 11, 1425-1432.	1.4	41
72	Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients with prior antiangiogenic therapy. Neuro-Oncology, 2018, 20, 259-267.	0.6	41

#	Article	IF	CITATIONS
73	Cerebrospinal Fluid Dissemination and Neoplastic Meningitis in Primary Brain Tumors. Cancer Control, 2017, 24, 1-16.	0.7	40
74	Recurrent spinal cord glioblastoma: salvage therapy with bevacizumab. Journal of Neuro-Oncology, 2011, 102, 427-432.	1.4	39
75	Neoplastic meningitis-related encephalopathy. Neurology, 2004, 63, 2159-2161.	1.5	37
76	Treatment options for glioblastoma. Neurosurgical Focus, 2006, 20, E19.	1.0	37
77	A pilot study of primary temozolomide chemotherapy and deferred radiotherapy in elderly patients with glioblastoma. Journal of Neuro-Oncology, 2007, 82, 207-209.	1.4	37
78	Prognostic significance of relative 1p/19q codeletion in oligodendroglial tumors. Journal of Neuro-Oncology, 2015, 125, 249-251.	1.4	37
79	The role of chemotherapy and targeted therapy in the treatment of intracranial meningioma. Current Opinion in Oncology, 2012, 24, 666-671.	1.1	35
80	Neoplastic meningitis. Current Neurology and Neuroscience Reports, 2008, 8, 249-258.	2.0	34
81	Neoplastic meningitis. Cancer, 2009, 115, 1941-1946.	2.0	34
82	Recurrent lymphomatous meningitis treated with intra-CSF rituximab and liposomal ara-C. Journal of Neuro-Oncology, 2009, 91, 271-277.	1.4	34
83	A novel treatment for glioblastoma: integrin inhibition. Expert Review of Neurotherapeutics, 2012, 12, 421-435.	1.4	34
84	Salvage therapy with bendamustine for methotrexate refractory recurrent primary CNS lymphoma: a retrospective case series. Journal of Neuro-Oncology, 2014, 118, 155-162.	1.4	34
85	Brain metastases: a medical neuro-oncology perspective. Expert Review of Neurotherapeutics, 2010, 10, 563-573.	1.4	33
86	Phase 1 dose escalation trial of the safety and pharmacokinetics of cabozantinib concurrent with temozolomide and radiotherapy or temozolomide after radiotherapy in newly diagnosed patients with highâ€grade gliomas. Cancer, 2016, 122, 582-587.	2.0	33
87	Myelomatous meningitis. Cancer, 2008, 112, 1562-1567.	2.0	32
88	Intracerebral meningiomas. Current Treatment Options in Neurology, 2004, 6, 297-305.	0.7	31
89	Comprehensive neuraxis imaging in leptomeningeal metastasis: a retrospective case series. CNS Oncology, 2013, 2, 121-128.	1.2	31
90	Complications related to the use of an intraventricular access device for the treatment of leptomeningeal metastases from solid tumor: a single centre experience in 112 patients. Journal of Neuro-Oncology, 2015, 124, 317-323.	1.4	31

#	Article	IF	CITATIONS
91	Neurolymphomatosis: a rare metastatic complication of diffuse large B-Cell lymphoma. Journal of Neuro-Oncology, 2009, 95, 285-288.	1.4	30
92	IFN-α for recurrent surgery- and radiation-refractory high-grade meningioma: a retrospective case series. CNS Oncology, 2013, 2, 227-235.	1.2	30
93	Phase I/II study of intraventricular and intrathecal ACNU for leptomeningeal neoplasia. Cancer Chemotherapy and Pharmacology, 1989, 23, 301-307.	1.1	29
94	The future of high-grade glioma: Where we are and where are we going. , 2015, 6, 9.		29
95	Neurotoxicity of Cancer Treatment. Current Oncology Reports, 2010, 12, 60-67.	1.8	27
96	A Bayesian adaptive randomized phase II multicenter trial of bevacizumab with or without vorinostat in adults with recurrent glioblastoma. Neuro-Oncology, 2020, 22, 1505-1515.	0.6	27
97	Extended exposure to alkylator chemotherapy: delayed appearance of myelodysplasia. Journal of Neuro-Oncology, 2009, 93, 229-232.	1.4	26
98	Salvage therapy with single agent bendamustine for recurrent glioblastoma. Journal of Neuro-Oncology, 2011, 105, 523-530.	1.4	25
99	Radiation-Induced Myelopathy. Archives of Neurology, 2011, 68, 1608.	4.9	25
100	Intradural intramedullary spinal cord metastasis due to mesothelioma. Journal of Neuro-Oncology, 2010, 97, 133-136.	1.4	24
101	Volumetric response quantified using T1 subtraction predicts long-term survival benefit from cabozantinib monotherapy in recurrent glioblastoma. Neuro-Oncology, 2018, 20, 1411-1418.	0.6	24
102	Salvage chemotherapy with CPTâ€11 for recurrent temozolomideâ€refractory anaplastic astrocytoma. Cancer, 2008, 112, 2038-2045.	2.0	23
103	Current Management of Adult Diffuse Infiltrative Low Grade Gliomas. Current Neurology and Neuroscience Reports, 2016, 16, 15.	2.0	23
104	High-dose cytarabine salvage therapy for recurrent primary CNS lymphoma. Journal of Neuro-Oncology, 2016, 126, 545-550.	1.4	22
105	Anticancer therapies and CNS relapse: overcoming blood–brain and blood–cerebrospinal fluid barrier impermeability. Expert Review of Neurotherapeutics, 2010, 10, 547-561.	1.4	20
106	Neoplastic Meningitis Due to Lung, Breast, and Melanoma Metastases. Cancer Control, 2017, 24, 22-32.	0.7	20
107	CPT-11 for recurrent temozolomide-refractory 1p19q co-deleted anaplastic oligodendroglioma. Journal of Neuro-Oncology, 2008, 89, 231-238.	1.4	19
108	Neoplastic Meningitis and Metastatic Epidural Spinal Cord Compression. Hematology/Oncology Clinics of North America, 2012, 26, 917-931.	0.9	19

#	Article	IF	CITATIONS
109	Neoplastic Meningitis. Seminars in Neurology, 2004, 24, 363-374.	0.5	18
110	Patterns of response to crizotinib in recurrent glioblastoma according to ALK and MET molecular profile in two patients. CNS Oncology, 2015, 4, 381-386.	1.2	18
111	Salvage therapy with lomustine for temozolomide refractory recurrent anaplastic astrocytoma: a retrospective study. Journal of Neuro-Oncology, 2015, 122, 329-338.	1.4	18
112	Neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphocytic leukemia. Blood, 2007, 110, 1698-1698.	0.6	17
113	CSF CA 15-3 in breast cancer-related leptomeningeal metastases. Journal of Neuro-Oncology, 2014, 117, 117-124.	1.4	17
114	Recurrent ganglioglioma in adults treated with BRAF inhibitors. CNS Oncology, 2016, 5, 27-29.	1.2	17
115	Posterior Reversible Encephalopathy Syndrome Associated With Dose-adjusted EPOCH (Etoposide,) Tj ETQq1 1 (and Leukemia, 2017, 17, 225-230.	0.784314 0.2	rgBT /Overloo 17
116	O6-methylguanine-DNA methyltransferase activity is associated with response to alkylating agent therapy and with MGMT promoter methylation in glioblastoma and anaplastic glioma. BBA Clinical, 2015, 3, 1-10.	4.1	16
117	Prolonged survival of patients with breast cancer-related leptomeningeal metastases. Anticancer Research, 2013, 33, 2057-63.	0.5	16
118	Recursive partitioning analysis of prognostic variables in newly diagnosed anaplastic oligodendroglial tumors. Neuro-Oncology, 2014, 16, 1541-1546.	0.6	12
119	Is there effective systemic therapy for recurrent surgery- and radiation-refractory meningioma?. CNS Oncology, 2013, 2, 1-5.	1.2	11
120	Flow-Related Aneurysm within Glioblastoma: A Case Report and Review of Literature. World Neurosurgery, 2016, 89, 729.e1-729.e6.	0.7	11
121	Leukemia and the nervous system. Current Oncology Reports, 2005, 7, 66-73.	1.8	10
122	Role for cytotoxic chemotherapy in patients with recurrent glioblastoma progressing on bevacizumab: a retrospective case series. Expert Review of Neurotherapeutics, 2012, 12, 929-936.	1.4	10
123	Prolonged Response and Restoration of Functional Independence with Bevacizumab plus Vinorelbine as Third-Line Treatment for Breast Cancer-Related Leptomeningeal Metastases. Case Reports in Oncology, 2015, 8, 72-77.	0.3	10
124	Salvage intracerebrospinal fluid thiotepa in breast cancer-related leptomeningeal metastases. Anti-Cancer Drugs, 2013, 24, 1093-1097.	0.7	9
125	Risk of neoplastic meningitis following surgical resection of cerebellar metastases. Journal of Neuro-Oncology, 2008, 89, 105-107.	1.4	8
126	Anaplastic astrocytomas: biology and treatment. Expert Review of Neurotherapeutics, 2008, 8, 575-586.	1.4	8

#	Article	IF	CITATIONS
127	Teaching Neuro <i>Images</i> : Sacral spine chloroma. Neurology, 2013, 81, e87.	1.5	8
128	Central Nervous System Involvement in Cutaneous T-Cell Lymphoma: 2 Illustrative Cases and a Review of Current Literature. Clinical Lymphoma, Myeloma and Leukemia, 2014, 14, e25-e30.	0.2	6
129	Treatment of primary CNS lymphoma (PCNSL) following successful treatment of systemic non-Hodgkin's lymphoma (NHL): a case series. Journal of Neuro-Oncology, 2013, 113, 27-32.	1.4	5
130	Are Prognostic Factors for Leptomeningeal Metastases Defined Sufficiently to Permit Tailored Treatment?. Journal of Thoracic Oncology, 2013, 8, e66-e67.	0.5	4
131	Is the volume of low-grade glioma measurable and is it clinically relevant?. Neuro-Oncology, 2014, 16, 1027-1028.	0.6	4
132	Bevacizumab and other novel therapies for recurrent oligodendroglial tumors. CNS Oncology, 2015, 4, 333-339.	1.2	4
133	Salvage therapy with bendamustine for temozolomide refractory recurrent anaplastic gliomas: a prospective phase II trial. Journal of Neuro-Oncology, 2017, 131, 507-516.	1.4	4
134	Is there a role for vaccine-based therapy in recurrent glioblastoma?. Neuro-Oncology, 2014, 16, 757-757.	0.6	3
135	Neoplastic meningitis-related encephalopathy. Journal of Neuro-Oncology, 2005, 72, 185-189.	1.4	2
136	Glioblastoma in the Elderly. Cancer Treatment and Research, 2015, 163, 159-170.	0.2	2
137	Lymphomatous meningitis as a presentation of non-Hodgkin lymphoma. Clinical Advances in Hematology and Oncology, 2011, 9, 419-20.	0.3	2
138	Lymphomatous Meningitis. American Journal of Cancer, 2002, 1, 423-434.	0.4	1
139	10 Questions About the Use of Bevacizumab in the Management of Recurrent Malignant Gliomas. Neurologist, 2010, 16, 56-60.	0.4	1
140	Neuro-oncology: a selected review of ASCO 2011 abstracts. Expert Review of Neurotherapeutics, 2011, 11, 1371-1377.	1.4	1
141	Carcinomatous meningitis. Memo - Magazine of European Medical Oncology, 2012, 5, 205-209.	0.3	1
142	Lumbar spine neuroarthropathy (Charcot joint) caused by a myxopapillary ependymoma. Journal of Neuro-Oncology, 2014, 117, 375-376.	1.4	1
143	Chemotherapy for Brain Metastases due to Lung Cancer and Melanoma. Cancer Treatment and Research, 2007, 136, 199-213.	0.2	1
144	Response to Weltman and Fleury Malheiros, re Lassman et al Neuro-Oncology, 2012, 14, 677-678.	0.6	0

#	Article	IF	CITATIONS
145	Conference Scene: A selected review of abstracts from the 17th Annual Scientific Meeting of the Society for Neuro-Oncology. CNS Oncology, 2013, 2, 117-120.	1.2	0
146	Does early identification of low-grade glioma growth impact outcome?. Neuro-Oncology, 2014, 16, 1296-1296.	0.6	0
147	A selected review of abstracts from the 20th Annual Meeting of the Society for Neuro-Oncology (SNO). CNS Oncology, 2016, 5, 115-119.	1.2	0
148	Neuro-oncology: a selected review of ASCO 2016 abstracts. CNS Oncology, 2016, 5, 193-198.	1.2	0
149	Neuro-oncology overview. , 2016, , 557-558.		0
150	"You can observe a lot by just watching―(Yogi Berra). Neuro-Oncology, 2022, 24, 125-126.	0.6	0
151	Leptomeningeal metastasis. , 2022, , 133-143.		Ο